Evidence map›Paper›PMID 40795579›Full record

ArticleStem cell research2025

Generation of an induced pluripotent stem cell line from a malignant melanoma patient who developed the immune checkpoint inhibitor-related myasthenia gravis, myositis, and myocarditis overlap syndrome.

Diem Thi Ngoc Huynh, Chikage Noishiki, Jacquelyn Lai, Pourya Yarahmadi, Thao Le, Dipti Tripathi, Ines Ross Tacco, Amit Manhas, Karim Sallam, Ian Y Chen and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Diem Thi Ngoc HuynhStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Chikage NoishikiStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Jacquelyn LaiStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Pourya YarahmadiStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Thao LeStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Dipti TripathiBaszucki Family Vascular Surgery Biobank, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ines Ross TaccoStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Amit ManhasStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Karim SallamStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Ian Y ChenStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.
Nazish SayedStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Baszucki Family Vascular Surgery Biobank, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: syedns@stanford.edu.
Patricia K NguyenStanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA. Electronic address: pknguyen@stanford.edu.

Funding

Deciphering the Endothelial Cell-Cardiomyocyte Crosstalk in LMNA CardiomyopathyR01HL158641 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2021 to 2025
$2.2M
Multimodality Molecular Imaging of Stem Cell Therapy for Ischemic CardiomyopathyR01HL134830 · NHLBI · STANFORD UNIVERSITY · PI NGUYEN, PATRICIA KIM PHUONG · 2017 to 2021
$2.1M
Unraveling the role of endothelium in chemotherapy-induced cardiotoxicityR01HL161002 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2022 to 2025
$1.6M
Organ system cross talk in ischemic heart diseaseR01AG086072 · NIA · STANFORD UNIVERSITY · PI Patricia Kim Phuong Nguyen · 2024 to 2026
$1.5M
NHLBI NIH HHS R01 HL134830NHLBI NIH HHS R01 HL158641NHLBI NIH HHS R01 HL161002NIA NIH HHS R01 AG086072
6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICI) are a pivotal class of immuno-oncology therapeutics that have improved survival rates for patients with cancer. Their widespread usage, however, is limited due to the development of serious and potentially deadly ICI-related side effects. To develop novel diagnostic and therapeutic strategies to identify and treat patients at risk, we need a better understanding of the underlying mechanisms mediating these potentially deadly side effects. To reach this goal, we have generated and validated induced pluripotent stem cells from the peripheral blood mononuclear cells of a melanoma patient who developed ICI-related myasthenia gravis, myositis, and myocarditis overlap syndrome.

Indexed as

Immune Checkpoint InhibitorsInduced Pluripotent Stem CellsMelanomaMyasthenia GravisMyocarditisMyositisHumansMaleMiddle AgedImmune Checkpoint InhibitorsHuman induced pluripotent stem cell (iPSC)Immune-checkpoint-inhibitorsMalignant melanomaMyasthenia gravis, myositis, and myocarditis overlap syndrome

Identifiers

PMID40795579
PMCPMC12450033

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.